New study compares effectiveness of GLP-1 weight loss drugs

A new meta-analysis from the University of Georgia has identified tirzepatide as the most effective GLP-1 medication for weight loss among non-diabetic patients. The study, which examined data from 14,000 individuals, found that tirzepatide, sold under brand names like Zepbound and Mounjaro, led to a loss of over 20% of starting body weight.

In comparison, semaglutide, known as Wegovy and Ozempic, resulted in approximately 15% weight loss, while liraglutide, marketed as Saxenda and Victoza, achieved about 8% weight loss. The researchers were interested in determining which drug offered the most significant weight loss without a higher incidence of side effects such as nausea and gastrointestinal issues.

Tirzepatide is considered a dual agonist, meaning it targets both GLP-1 and GIP hormone receptors, differentiating it from semaglutide and liraglutide, which primarily target GLP-1 receptors. According to Pooja Gokhale, an author of the review, tirzepatide appears to be the superior option based on the findings, particularly at higher doses.